With respect to treatment of malignant disease, increased expression of Hsp-27 has been linked to vincristine resistance in gastric cancer (Yang et al, 2009) and to 5-fluorouracil resistance in colon cancer (Tsuruta et al, 2008), and breast cancer cells initially over-expressing Hsp-27 became sensitive to doxorubicin after modulation of endogenous Hsp-27 levels by paclitaxel (Shi et al, 2008). Here, HSPB1 is linked to breast carcinoma.